# Clovis Oncology

Source: https://onco.cc/companies/clovis-oncology/  
OnCo record `clovis-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023.

## Summary

Clovis Oncology, based in Boulder, Colorado and listed on Nasdaq, developed rucaparib (Rubraca), a PARP inhibitor approved in the United States from 2016 for BRCA-mutated ovarian cancer, then as maintenance therapy (ARIEL3) and for BRCA-mutated metastatic castration-resistant prostate cancer (TRITON2). An earlier lead, the EGFR inhibitor rociletinib, was abandoned in 2016 after disputed response data. Competition from other PARP inhibitors and a restricted label left the company unable to service its debt; it filed for Chapter 11 in December 2022 and sold Rubraca to pharma& in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Clovis Oncology, Inc.
- Tags: ctgov-sponsor
- HQ: Boulder, CO
- Type: biotech
- Website: https://www.clovisoncology.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Clovis_Oncology
- ClinicalTrials.gov: trials led by Clovis Oncology: https://clinicaltrials.gov/search?lead=Clovis%20Oncology
- Wikipedia: https://en.wikipedia.org/wiki/Clovis_Oncology

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Rucaparib](https://onco.cc/drugs/rucaparib/)
- trials: [ATHENA-MONO / GOG-3020](https://onco.cc/trials/athena-mono/), [Pan Tumor Rollover Study](https://onco.cc/trials/nct03899155/), [TRITON3](https://onco.cc/trials/triton3/)
- key papers: [TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration](https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/), [TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/)
- companies: [pharma&](https://onco.cc/companies/pharmaand/)

---
JSON: https://onco.cc/api/v1/entities/clovis-oncology.json